Thomas C. Geiser was appointed to the board of directors of SCA in 2007. Mr. Geiser has served as a TPG Senior Advisor since 2006 and served as the Executive Vice President and General Counsel of WellPoint Health Networks Inc. (“WellPoint”) from its inception in 1993 to 2005. Mr. Geiser was responsible for WellPoint’s legal, legislative and regulatory affairs in fifty states and served as its principal contact with state and federal regulators. Prior to joining WellPoint, Mr. Geiser worked as an attorney in private law practice, coming to WellPoint from Brobeck, Phleger & Harrison LLP in San Francisco. He currently serves on the board of directors for Novasom, Inc., Origin, Inc. d/b/a Shiftwise and the Library Foundation of Los Angeles, and previously served on the board of directors of Saint John’s Health Center. Mr. Geiser earned his J.D. from the University of California, Hastings College of the Law and earned his undergraduate degree in English from the University of Redlands. Mr. Geiser has extensive expertise and experience providing leadership in legal, legislative, regulatory and compliance affairs to both public and private companies in the healthcare industry.
Kenneth R. Goulet was appointed to the board of directors of SCA in 2016. Mr. Goulet served in a number of roles with Anthem, Inc., one of the nation's leading health benefits companies, from 2004 until his retirement on October 1, 2015, including most recently as Executive Vice President, and President of Anthem's Commercial and Specialty Business. Previously, Mr. Goulet spent 23 years at CIGNA Corporation, where he held a number of management, sales and operations positions. He currently serves on the Board of Cotiviti (COTV) as well as Sharecare, IPG and EmpiRx Health. Mr. Goulet has substantial experience in the health care industry and his 30+ years tenure in growing and leading large health plan organizations and consumer-focused service operations make him a valuable asset to the Board. Mr. Goulet earned his bachelor of science in economics from Trinity College in Hartford, Conn.
Andrew serves as President and Chief Executive Officer of SCA, and he is Chairman of SCA’s board of directors. Prior to SCA, Andrew served as the President of a division of DaVita Healthcare Partners Inc. (a renal dialysis provider) and as President and Chief Operating Officer of Alliance Healthcare Services Inc. (a diagnostic imaging and radiation therapy provider). Andrew worked previously at Kohlberg Kravis Roberts & Co. (a private equity firm), and the Boston Consulting Group (a strategy consulting firm). Andrew serves on the board of advisors of Sg2 (a healthcare analytics company) and is a Henry Crown Fellow at the Aspen Institute. He earned a Bachelor of Arts summa cum laude (highest honors) from Yale University.
Frederick A. Hessler was appointed to the board of directors of SCA in 2013. Mr. Hessler is a retired Managing Director of Citigroup Global Markets Inc., where he headed the Not-for-Profit Health Care Investment Banking Group from 1990 to 2013. Prior to joining Citigroup Global Markets Inc. in 1985, Mr. Hessler was a Partner and Regional Director for healthcare at Ernst & Young LLP, where he was responsible for conducting audits and performing feasibility, corporate reorganization and strategic planning studies for healthcare clients. Mr. Hessler serves on the Operations Committee and chairs the Investment Committee for the American Hospital Association and is a board member of The Center for Health Design, the National Center for Healthcare Leadership and the Public Health Institute. Mr. Hessler also previously served as chair of the Board of Trustees of the Health Research and Education Trust and the Health Insights Foundation and was a member of The Center for Healthcare Governance’s Blue Ribbon Panel on Trustee Core Competencies and the Healthcare Executives Study Society. Mr. Hessler earned his bachelor’s degree in accounting from Wayne State University and is a Certified Public Accountant (inactive status). Mr. Hessler’s financial and accounting expertise and his substantial investment banking and advisory experience in the healthcare industry make him a valuable asset to the board of directors.
Sharad Mansukani, M.D. was appointed to the board of directors of SCA in 2007. Dr. Mansukani has served as a TPG Senior Advisor since 2005. He serves on the board of directors of IASIS Healthcare Corp., Immucor Inc., IMS Health Incorporated and Par Pharmaceuticals Companies, Inc. Dr. Mansukani serves as Strategic Advisor to the board of directors of CIGNA and previously served as Vice Chairman of HealthSpring Inc. Dr. Mansukani also serves on the board of directors of the Children’s Hospital of Philadelphia and on the editorial boards of the American Journal of Medical Quality , Managed Care , Biotechnology Healthcare and American Health & Drug Benefits . Dr. Mansukani was appointed to Medicare’s Payment Advisory and Oversight Committee, and he was previously Senior Advisor to CMS and a member of the Medicare Reform Executive Committee. Dr. Mansukani previously served on the faculty at the University of Pennsylvania and at Temple University School of Medicine. Dr. Mansukani completed his residency and fellowship in ophthalmology at the University of Pennsylvania School of Medicine and a fellowship in quality management and managed care at the Wharton School of the University of Pennsylvania. Dr. Mansukani has substantial experience in the healthcare industry and has a deep understanding of the medical community and the dynamic regulatory and reimbursement environment.
Jeffrey K. Rhodes was appointed to the board of directors of SCA in 2010. Mr. Rhodes is a Partner in the TPG San Francisco office, where he is a leader of the firm’s investment activities in the healthcare services, pharmaceutical and medical device sectors. In addition to SCA, Mr. Rhodes is actively involved with TPG’s investments in Biomet, EnvisionRx, Immucor, IMS Health, and Par Pharmaceuticals Companies. Prior to joining TPG’s San Francisco office in 2005, Mr. Rhodes worked at McKinsey & Company and Article27 LTD, a start-up software company. Mr. Rhodes earned his M.B.A. from the Harvard Business School, where he was a Baker Scholar, and earned his B.A., Summa Cum Laude, in Economics from Williams College. Mr. Rhodes’ financial expertise and experience overseeing investments in numerous healthcare companies makes him a valuable asset to the board of directors.
Michael A. Sachs was appointed to the board of directors of SCA effective September 1, 2015. Mr. Sachs serves as Senior Advisor and Board Observer at Healthbox, LLC and as a Member of the Board of the CEO Advisor Group at Alpha Capital Partners, Ltd. Mr. Sachs served as Chairman and Chief Executive Officer of Sg2, LLC until February 2013. Sg2 was subsequently sold to MedAssets. Prior to founding Sg2, Mr. Sachs served as the Chairman and CEO of Sachs Group, which provided health care planning and marketing services to hospitals and health plans. Mr. Sachs also co-founded bSwift, LLC, an online benefits administration firm that was acquired by Aetna. Previously, Mr. Sachs was also a consultant with Ernst & Whinney and with AT Kearney. Mr. Sachs is a frequent lecturer on the future of health care and the impact of business and economic changes on the delivery of care. Mr. Sachs received a B.A. in Science and a Master of Science in Public Health in Health Management from the University of Missouri-Columbia.
Todd B. Sisitsky was appointed to the board of directors of SCA in 2007. Mr. Sisitsky is a Partner of TPG where he leads TPG’s investment activities in the healthcare sector globally. Mr. Sisitsky serves on the board of directors of Aptalis Pharma, Inc., formerly Axcan Pharma, IASIS Healthcare Corp., HealthScope Ltd., Immucor Inc., IMS Health Incorporated and Par Pharmaceuticals Companies, Inc. and previously served on the boards of Biomet Inc. and Fenwal Inc. He also serves on the board of the Campaign for Tobacco Free Kids, a global not-for-profit organization, and the Dartmouth Medical School Board of Overseers. Prior to joining TPG in 2003, Mr. Sisitsky worked at Forstmann Little & Company and Oak Hill Capital Partners. Mr. Sisitsky earned an M.B.A. from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar, and earned his undergraduate degree from Dartmouth College, where he graduated summa cum laude . Mr. Sisitsky’s financial expertise and experience leading investments in numerous healthcare companies make him a valuable asset to the board of directors.
Lisa Skeete Tatum was appointed to the board of directors of SCA effective October 1, 2014. Ms. Skeete Tatum began her career at Procter & Gamble in 1989 where she served in various functional roles including Product Development, Purchasing, and Product Supply. From 1994 until 1995, she served as a Managing Director of Circle of Beauty, a health and beauty joint venture funded by Sears. She also worked for GE Capital and founded her own consulting firm in 1995, specializing in strategic operational development for medium-sized consumer products companies. Ms. Skeete Tatum was a General Partner at Cardinal Partners, an early stage health care venture capital firm, for over a decade where she focused on investments in healthcare technology. Ms. Skeete Tatum is on the board of trustees for Cornell University and the boards of the Princeton Healthcare System Foundation and the Princeton Area Community Foundation. She is a past president of the Harvard Business School Alumni Board and a former founding board member of the Center for Venture Education. She is a member of the 2012 Class of Henry Crown Fellows at the Aspen Institute and the Kauffman Fellows Class 4. Currently, Ms. Skeete Tatum is an advisor and investor based in Princeton, New Jersey.